Infosys today said that it will design and implement its research informatics system (RISe) for Dublin-based biotechnology drug firm Elan Pharmaceuticals, to accelerate discovery research using a path-breaking co-creation engagement model that leverages Infosys' existing intellectual property in this field.
The co-creation engagement model enables Infosys to retain ownership of co-developed intellectual property as part of the implementation. Relevant components of this reference implementation can be reused or repurposed by Infosys to deliver faster business benefits at other life sciences organisations.
For Elan, the deal would enable it to lower its costs for scientific operations. The new system will also reduce the time Elan would spend on registering and experimenting with bio-entities, increase collaboration, and reduce chances of downstream failure.
"As Elan's informatics system, RISe will leverage Infosys' Scientific Innovation Solution for knowledge collaboration," Infosys said in a statement.
It said novel ways to unlock disparate data spread across in-house research labs and other commercial or public sources will be presented to scientists in context of their research needs. This will result in, among other things, a customised registry, and inventory and a workflow management system for biological entities.
"We are confident that partnering and collaborating with Infosys will create a comprehensive informatics platform for our discovery research needs," said Ajay Shah, director, research informatics, Elan Pharmaceuticals.